Wyeth Sales Growth Not Dependent On Effexor XR, CEO Essner Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company plans to file six NDAs over the next 24 months, including the Effexor follow-on drug DVS-233. Wyeth believes the antidepressant market will eventually "start to swing back" since the products are safe and effective "within the confines of their labeling."